The court granted final approval on May 16, 2024. The November 30, 2024 claim deadline has passed, and the official settlement site does not post a current confirmation that distribution is complete.
StatusFinal approval; claims closed
Claim DeadlineNovember 30, 2024 (Passed)
Estimated Class BenefitsApproximately $41.47 million
Individual BenefitGenerally $10 to $50
What Was This Case About?
The lawsuit alleged that Acella Pharmaceuticals misleadingly marketed NP Thyroid despite allegedly incorrect active-ingredient strength in certain medication. Acella denied the claims and did not admit wrongdoing.
Who Was Covered?
The class included natural persons in the United States for whom an NP Thyroid prescription was dispensed from May 12, 2018 through April 30, 2021, whether or not the prescription came from a recalled lot.
What Benefits Were Available?
Eligible claimants could receive at least $10 and up to $50 based on documented out-of-pocket costs. Proof that an eligible prescription was dispensed was required, and prior participation in certain Acella refund programs could affect eligibility.